From Financial Modeling Prep: 2025-05-02 13:03:00

Amgen reported adjusted earnings per share of $4.90, a 24% increase from the previous year, surpassing expectations. Total revenues for Q1 2025 reached $8.1 billion, a 9% increase, driven by strong product demand. Key drugs like Prolia saw revenue hit $1.1 billion, a 10% increase, outperforming sales expectations.



Read more at Financial Modeling Prep:: Amgen Inc. (NASDAQ:AMGN) Surpasses Earnings and Sa…